Goodbye ‘340B,’ Hello ‘Outpatient Drug Discount Program’ In House Reform Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
House Commerce Committee members are drafting legislation to make numerous significant changes to the 340B drug discount program, including the definition of eligible patients, new reporting and auditing requirements for providers and drug manufacturers, rules for contract pharmacies – and a new user-fee program for participating health care providers.
You may also be interested in...
340B Reform May Return To Capitol Hill: Hearings Will Play To New HRSA Leadership
Rep. Chris Collins (R-NY) plans to introduced a bill to reform the 340B drug discount program in the coming weeks, and says he has a commitment from the House Energy & Commerce Committee leadership to consider the bill in hearings over the summer; that in turn may help shape HRSA’s oversight of the program in the Trump Administration.
340B Drug Discount Program Hits A Turning Point, But In Which Direction?
Long-awaited “mega-guidance” sets boundaries on discount and makes big changes for HIV drugs – and could mean the beginning of the end of the scrutiny of the program. A legislative proposal floated in the context of the “21st Century Cures” bill might move things in a different direction.
340B Needs Legislative Fix For Overspending On Medicare Patients, GAO Says
Drug discount program creates financial incentive for participating hospitals to prescribe more drugs or more expensive drugs reimbursed by Medicare Part B, resulting in 'substantially higher' spending, a GAO report says.